Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors

Frontiers in Cellular Neuroscience

Volumn , Issue JUNE, 2013, Pages

  Merienne, N ^a   Le Douce, J ^a   Faivre, E ^a   Deglon N ^a   Bonvento, G ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Astrocytes; CNS; Gene therapy; Tropism; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; BACULOVIRUS VECTOR; CALCINEURIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GANCICLOVIR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN 2; LENTIVIRUS VECTOR; LONTUCIREV; MICRORNA; NEURTURIN; ONCOLYTIC HERPES VIRUS; PARVOVIRUS VECTOR; THYMIDINE KINASE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CANCER GENE THERAPY; GENE EXPRESSION REGULATION; GENE TARGETING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; MOLONEY LEUKEMIA ONCOVIRUS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; REGULATORY SEQUENCE; SUICIDE GENE THERAPY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL TROPISM; VIRUS ENTRY; VIRUS PARTICLE;

EID: 84879164527     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00106     Document Type: Article

References (157)

1. Araque, A., Parpura, V., Sanzgiri, R.P., and Haydon, P.G. (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22, 208-215.
2. Arnberg, N. (2012). Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci 33, 442-448.
3. Arregui, L., Benitez, J.A., Razgado, L.F., Vergara, P., and Segovia, J. (2011). Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype. Cell Mol Neurobiol 31, 1229-1243.
4. Asadi-Moghaddam, K., and Chiocca, E.A. (2009). Gene- and viral-based therapies for brain tumors. Neurotherapeutics 6, 547-557.
5. Bak, M., Silahtaroglu, A., Moller, M., Christensen, M., Rath, M.F., Skryabin, B., Tommerup, N., and Kauppinen, S. (2008). MicroRNA expression in the adult mouse central nervous system. RNA 14, 432-444.
6. Barres, B.A. (2008). The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-440.
7. Bartel, D.P., and Chen, C.Z. (2004). Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5, 396-400.
8. Bartlett, J.S., Samulski, R.J., and Mccown, T.J. (1998). Selective and rapid uptake of adenoassociated virus type 2 in brain. Hum Gene Ther 9, 1181-1186.
9. Bell, C.L., Gurda, B.L., Van Vliet, K., Agbandje-Mckenna, M., and Wilson, J.M. (2012). Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol 86, 7326-7333.
10. Bell, C.L., Vandenberghe, L.H., Bell, P., Limberis, M.P., Gao, G.P., Van Vliet, K., Agbandje- Mckenna, M., and Wilson, J.M. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. Journal of Clinical Investigation 121, 2427-2435.
11. Bjorklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., and Mandel, R.J. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886, 82-98
12. Bohn, M.C., Choi-Lundberg, D.L., Davidson, B.L., Leranth, C., Kozlowski, D.A., Smith, J.C., O'banion, M.K., and Redmond, D.E., Jr. (1999). Adenovirus-mediated transgene expression in nonhuman primate brain. Hum Gene Ther 10, 1175-1184.
13. Boivin, G., Erice, A., Crane, D.D., Dunn, D.L., and Balfour, H.H., Jr. (1993). Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother 37, 357-359.
14. Boulaire, J., Zhao, Y., and Wang, S. (2009). Gene expression profiling to define host response to baculoviral transduction in the brain. J Neurochem 109, 1203-1214.
15. Bradford, J., Shin, J.Y., Roberts, M., Wang, C.E., Li, X.J., and Li, S. (2009). Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106, 22480-22485.
16. Bradford, J., Shin, J.Y., Roberts, M., Wang, C.E., Sheng, G., Li, S., and Li, X.J. (2010). Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem.
17. Brenner, M., Kisseberth, W.C., Su, Y., Besnard, F., and Messing, A. (1994). GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 14, 1030-1037.
18. Brown, B.D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., and Naldini, L. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25, 1457-1467.
19. Buffo, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A.P., Mori, T., and Gotz, M. (2008). Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc Natl Acad Sci U S A 105, 3581-3586.
20. Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J., and Muzyczka, N. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10, 302-317.
21. Cahoy, J.D., Emery, B., Kaushal, A., Foo, L.C., Zamanian, J.L., Christopherson, K.S., Xing, Y., Lubischer, J.L., Krieg, P.A., Krupenko, S.A., Thompson, W.J., and Barres, B.A. (2008). A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28, 264-278.
22. Candolfi, M., Curtin, J.F., Xiong, W.D., Kroeger, K.M., Liu, C., Rentsendorj, A., Agadjanian, H., Medina-Kauwe, L., Palmer, D., Ng, P., Lowenstein, P.R., and Castro, M.G. (2006). Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther 14, 371-381.
23. Cannon, J.R., Sew, T., Montero, L., Burton, E.A., and Greenamyre, J.T. (2011). Pseudotypedependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol 228, 41-52.
24. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Bougneres, P., Schmidt, M., Kalle, C.V., Fischer, A., Cavazzana-Calvo, M., and Aubourg, P. (2012). Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol 507, 187-198.
25. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrere, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., L'homme, B., Bougneres, P., Von Kalle, C., Fischer, A., Cavazzana- Calvo, M., and Aubourg, P. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
26. Castro, M.G., Candolfi, M., Kroeger, K., King, G.D., Curtin, J.F., Yagiz, K., Mineharu, Y., Assi, H., Wibowo, M., Ghulam Muhammad, A.K., Foulad, D., Puntel, M., and Lowenstein, P.R. (2011). Gene therapy and targeted toxins for glioma. Curr Gene Ther 11, 155-180.
27. Cearley, C.N., and Wolfe, J.H. (2006). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13,528-537.
28. Chiocca, E.A., Abbed, K.M., Tatter, S., Louis, D.N., Hochberg, F.H., Barker, F., Kracher, J., Grossman, S.A., Fisher, J.D., Carson, K., Rosenblum, M., Mikkelsen, T., Olson, J., Markert, J., Rosenfeld, S., Nabors, L.B., Brem, S., Phuphanich, S., Freeman, S., Kaplan, R., and Zwiebel, J. (2004). A phase I open-label, dose-escalation, multiinstitutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10, 958-966.
29. Cockrell, A.S., and Kafri, T. (2007). Gene delivery by lentivirus vectors. Mol Biotechnol 36, 184-204.
30. Coil, D.A., and Miller, A.D. (2004). Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 78, 10920-10926.
31. Colin, A., Faideau, M., Dufour, N., Auregan, G., Hassig, R., Andrieu, T., Brouillet, E., Hantraye, P., Bonvento, G., and Deglon, N. (2009). Engineered lentiviral vector targeting astrocytes in vivo. Glia 57, 667-679.
32. Cottin, S., Gould, P.V., Cantin, L., and Caruso, M. (2011). Gap junctions in human glioblastomas: implications for suicide gene therapy. Cancer Gene Ther 18, 674-681.
33. Crystal, R.G., Sondhi, D., Hackett, N.R., Kaminsky, S.M., Worgall, S., Stieg, P., Souweidane, M., Hosain, S., Heier, L., Ballon, D., Dinner, M., Wisniewski, K., Kaplitt, M., Greenwald, B.M., Howell, J.D., Strybing, K., Dyke, J., and Voss, H. (2004). Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 15, 1131-1154.
34. Custer, S.K., Garden, G.A., Gill, N., Rueb, U., Libby, R.T., Schultz, C., Guyenet, S.J., Deller, T., Westrum, L.E., Sopher, B.L., and La Spada, A.R. (2006). Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nature Neuroscience 9, 1302-1311.
35. Dabir, D.V., Robinson, M.B., Swanson, E., Zhang, B., Trojanowski, J.Q., Lee, V.M., and Forman, M.S. (2006). Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci 26, 644-654.
36. Das, T., Jaffar-Bandjee, M.C., Hoarau, J.J., Krejbich Trotot, P., Denizot, M., Lee-Pat-Yuen, G., Sahoo, R., Guiraud, P., Ramful, D., Robin, S., Alessandri, J.L., Gauzere, B.A., and Gasque, P. (2010). Chikungunya fever: CNS infection and pathologies of a reemerging arbovirus. Prog Neurobiol 91, 121-129.
37. Davidson, B.L., and Breakefield, X.O. (2003). Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4, 353-364.
38. Davidson, B.L., Stein, C.S., Heth, J.A., Martins, I., Kotin, R.M., Derksen, T.A., Zabner, J., Ghodsi, A., and Chiorini, J.A. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97, 3428-3432.
39. Déglon, N., and Hantraye, P. (2005). Viral vectors as tools to model and treat neurodegenerative disorders. J Gene Med 7, 530-539.
40. Déglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y., Pereira De Almeida, L., Zufferey, R., Trono, D., and Aebischer, P. (2000). Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 11, 179-190.
41. Delelis, O., Zamborlini, A., Thierry, S., and Saib, A. (2010). Chromosomal tethering and proviral integration. Biochim Biophys Acta 1799, 207-216.
42. Deo, M., Yu, J.Y., Chung, K.H., Tippens, M., and Turner, D.L. (2006). Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev Dyn 235, 2538-2548.
43. Di Pasquale, G., Davidson, B.L., Stein, C.S., Martins, I., Scudiero, D., Monks, A., and Chiorini, J.A. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9, 1306-1312.
44. Do Thi, N.A., Saillour, P., Ferrero, L., Dedieu, J.F., Mallet, J., and Paunio, T. (2004). Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther 11, 746-756.
45. Drinkut, A., Tereshchenko, Y., Schulz, J.B., Bahr, M., and Kugler, S. (2012). Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 20, 534-543.
46. Edbauer, D., Neilson, J.R., Foster, K.A., Wang, C.F., Seeburg, D.P., Batterton, M.N., Tada, T., Dolan, B.M., Sharp, P.A., and Sheng, M. (2010). Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65, 373-384.
47. Englund, U., Ericson, C., Rosenblad, C., Mandel, R.J., Trono, D., Wictorin, K., and Lundberg, C. (2000). The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS. Neuroreport 11, 3973-3977.
48. Faideau, M., Kim, J.H., Cormier, K., Gilmore, R., Welch, M., Auregan, G., Dufour, N., Guillermier, M., Brouillet, E., Hantraye, P., Deglon, N., Ferrante, R.J., and Bonvento, G. (2010). In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Human Molecular Genetics 19, 3053-3067.
49. Federoff, H.J., Geschwind, M.D., Geller, A.I., and Kessler, J.A. (1992). Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci U S A 89, 1636-1640.
50. Forman, M.S., Lal, D., Zhang, B., Dabir, D.V., Swanson, E., Lee, V.M., and Trojanowski, J.Q. (2005). Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 25, 3539-3550.
51. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., and Kaspar, B.K (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27, 59-65.
52. Frampton, A.R., Jr., Goins, W.F., Nakano, K., Burton, E.A., and Glorioso, J.C. (2005). HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 12, 891-901.
53. Freeman, M.R. (2010). Specification and Morphogenesis of Astrocytes. Science 330, 74-778.
54. Furman, J.L., Sama, D.M., Gant, J.C., Beckett, T.L., Murphy, M.P., Bachstetter, A.D., Van Eldik, L.J., and Norris, C.M. (2012). Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32, 16129-16140.
55. Gash, D.M., Zhang, Z.M., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J., and Gerhardt, G.A. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255.
56. Geller, A.I., and Breakefield, X.O. (1988). A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241, 1667-1669.
57. Gentner, B., and Naldini, L. (2012). Exploiting microRNA regulation for genetic engineering. Tissue Antigens 80, 393-403.
58. Gentner, B., Schira, G., Giustacchini, A., Amendola, M., Brown, B.D., Ponzoni, M., and Naldini, L. (2009). Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6, 63-66.
59. Gerstein, M.B., Kundaje, A., Hariharan, M., Landt, S.G., Yan, K.K., Cheng, C., Mu, X.J., Khurana, E., Rozowsky, J., Alexander, R., Min, R., Alves, P., Abyzov, A., Addleman, N., Bhardwaj, N., Boyle, A.P., Cayting, P., Charos, A., Chen, D.Z., Cheng, Y., Clarke, D., Eastman, C., Euskirchen, G., Frietze, S., Fu, Y., Gertz, J., Grubert, F., Harmanci A., Jain, P., Kasowski, M., Lacroute, P., Leng, J., Lian, J., Monahan, H., O'geen, H., Ouyang, Z., Partridge, E.C., Patacsil, D., Pauli, F., Raha, D., Ramirez, L., Reddy, T.E., Reed, B., Shi, M., Slifer, T., Wang, J., Wu, L., Yang, X., Yip, K.Y., Zilberman- Schapira, G., Batzoglou, S., Sidow, A., Farnham, P.J., Myers, R.M., Weissman, S.M., and Snyder, M. (2012). Architecture of the human regulatory network derived from ENCODE data. Nature 489, 91-100.
60. Ghulam Muhammad, A.K., Candolfi, M., King, G.D., Yagiz, K., Foulad, D., Mineharu, Y., Kroeger, K.M., Treuer, K.A., Nichols, W.S., Sanderson, N.S., Yang, J., Khayznikov, M., Van Rooijen, N., Lowenstein, P.R., and Castro, M.G. (2009). Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15, 6113-6127.
61. Gong, Y., Chen, S., Sonntag, C.F., Sumners, C., Klein, R.L., King, M.A., Hughes, J.A., and Meyer, E.M. (2004). Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia. Brain Res Brain Res Protoc 14, 18-24.
62. Gray, S.J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S.R., and Samulski, R.J. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19, 1058-1069.
63. Grellier, E., Lecolle, K., Rogee, S., Couturier, C., D'halluin, J.C., Hong, S.S., Fender, P., Boulanger, P., Quesnel, B., and Colin, M. (2011). A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. Mol Cancer 10, 105.
64. Grossman, S.A., Ye, X., Piantadosi, S., Desideri, S., Nabors, L.B., Rosenfeld, M., and Fisher, J. (2010). Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16, 2443-2449.
65. Gu, X., Li, C., Wei, W., Lo, V., Gong, S., Li, S.H., Iwasato, T., Itohara, S., Li, X.J., Mody, I., Heintz, N., and Yang, X.W. (2005). Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433-444.
66. Gunzburg, W.H., Saller, R.M., and Salmons, B. (1995). Retroviral vectors directed to predefined cell types for gene therapy. Biologicals 23, 5-12.
67. Hawrylycz, M.J., Lein, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L., Miller, J.A., Van De Lagemaat, L.N., Smith, K.A., Ebbert, A., Riley, Z.L., Abajian, C., Beckmann, C.F., Bernard, A., Bertagnolli, D., Boe, A.F., Cartagena, P.M., Chakravarty, M.M., Chapin, M., Chong, J., Dalley, R.A., Daly, B.D., Dang, C., Datta, S., Dee, N., Dolbeare, T.A., Faber, V., Feng, D., Fowler, D.R., Goldy, J., Gregor, B.W., Haradon, Z., Haynor, D.R., Hohmann, J.G., Horvath, S., Howard, R.E., Jeromin, A., Jochim, J.M., Kinnunen, M., Lau, C., Lazarz, E.T., Lee, C., Lemon, T.A., Li, L., Li, Y., Morris, J.A., Overly, C.C., Parker, P.D., Parry, S.E., Reding, M., Royall, J.J., Schulkin, J., Sequeira, P.A., Slaughterbeck, C.R., Smith, S.C., Sodt, A.J., Sunkin, S.M., Swanson, B.E., Vawter, M.P., Williams, D., Wohnoutka, P., Zielke, H.R., Geschwind, D.H., Hof, P.R., Smith, S.M., Koch, C., Grant, S.G., and Jones, A.R. (2012). An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391-399.
68. He, M., Liu, Y., Wang, X., Zhang, M.Q., Hannon, G.J., and Huang, Z.J. (2012). Cell-typebased analysis of microRNA profiles in the mouse brain. Neuron 73, 35-48.
69. Hermens, W.T., and Verhaagen, J. (1997). Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. Hum Gene Ther 8, 1049-1063.
70. Horellou, P., Vigne, E., Castel, M.N., Barneoud, P., Colin, P., Perricaudet, M., Delaere, P., and Mallet, J. (1994). Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 6, 49-53.
71. Horst, M., Brouwer, E., Verwijnen, S., Rodijk, M., De Jong, M., Hoeben, R., De Leeuw, B., and Smitt, P.S. (2007). Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 9, 1071-1079.
72. Ilieva, H., Polymenidou, M., and Cleveland, D.W. (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. Journal of Cell Biology 187, 761-772.
73. Jakobsson, J., Georgievska, B., Ericson, C., and Lundberg, C. (2004). Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector. Eur J Neurosci 19, 761-765.
74. Jarraya, B., Boulet, S., Ralph, G.S., Jan, C., Bonvento, G., Azzouz, M., Miskin, J.E., Shin, M., Delzescaux, T., Drouot, X., Herard, A.S., Day, D.M., Brouillet, E., Kingsman, S.M., Hantraye, P., Mitrophanous, K.A., Mazarakis, N.D., and Palfi, S. (2009). Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1, 2ra4.
75. Jerusalinsky, D., Baez, M.V., and Epstein, A.L. (2012). Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. J Physiol Paris 106, 2-11.
76. Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D., and During, M.J. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097-2105.
77. Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'malley, K.L., and During, M.J. (1994). Long-term gene expression and phenotypic correction using adenoassociated virus vectors in the mammalian brain. Nat Genet 8, 148-154.
78. Kay, M.A., Glorioso, J.C., and Naldini, L. (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7, 33-40.
79. Kern, A., Schmidt, K., Leder, C., Muller, O.J., Wobus, C.E., Bettinger, K., Von Der Lieth, C.W., King, J.A., and Kleinschmidt, J.A. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77, 11072-11081.
80. Kirik, D., Annett, L.E., Burger, C., Muzyczka, N., Mandel, R.J., and Bjorklund, A. (2003). Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 100, 2884-2889.
81. Kirik, D., Rosenblad, C., Bjorkland, A., and Mandel, R.J. (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. Journal of Neuroscience 20, 4686-4700.
82. Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.L., and Philippon, J. (1998). A phase I/II study of herpes simplex virus type 1 thymidine kinase suicide gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9, 2595-2604.
83. Klein, R.L., Dayton, R.D., Tatom, J.B., Henderson, K.M., and Henning, P.P. (2008). AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 16, 89-96.
84. Kordower, J.H., Bloch, J., Ma, S.Y., Chu, Y., Palfi, S., Roitberg, B.Z., Emborg, M., Hantraye, P., Deglon, N., and Aebischer, P. (1999). Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160, 1-16.
85. Kosik, K.S. (2006). The neuronal microRNA system. Nat Rev Neurosci 7, 911-920.
86. Kroeger, K.M., Muhammad, A.K., Baker, G.J., Assi, H., Wibowo, M.K., Xiong, W., Yagiz, K., Candolfi, M., Lowenstein, P.R., and Castro, M.G. (2010). Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med 10, 293-304.
87. Kugler, S., Lingor, P., Scholl, U., Zolotukhin, S., and Bahr, M. (2003). Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311, 89-95.
88. Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol 12, 735-739.
89. Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G., Moro, E., Heywood, P., Brodsky, M.A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., Wooten, V.G.F., Elias, W.J., Laws, E.R., Dhawan, V., Stoessl, A.J., Matcham, J., Coffey, R.J., and Traub, M. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 59, 459-466.
90. Lawlor, P.A., Bland, R.J., Mouravlev, A., Young, D., and During, M.J. (2009). Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17, 1692-1702.
91. Le Gal La Salle, G., Robert, J.J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L.D., Perricaudet, M., and Mallet, J. (1993). An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259, 988-990.
92. Lee, Y., Messing, A., Su, M., and Brenner, M. (2008). GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56, 481-493.
93. Lewis, T.B., Glasgow, J.N., Glandon, A.M., Curiel, D.T., and Standaert, D.G. (2010). Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy. PLoS One 5.
94. Li, M., Husic, N., Lin, Y., Christensen, H., Malik, I., Mciver, S., Lapash Daniels, C.M., Harris, D.A., Kotzbauer, P.T., Goldberg, M.P., and Snider, B.J. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods 189, 56-64.
95. Liu, G., Martins, I.H., Chiorini, J.A., and Davidson, B.L. (2005). Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther 12, 1503-1508.
96. Liu, X., Bolteus, A.J., Balkin, D.M., Henschel, O., and Bordey, A. (2006). GFAP-expressing cells in the postnatal subventricular zone display a unique glial phenotype intermediate between radial glia and astrocytes. Glia 54, 394-410.
97. Lundberg, C., Bjorklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Deglon, N., and Kirik, D. (2008). Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. Current Gene Therapy 8, 461-473.
98. Lutschg, V., Boucke, K., Hemmi, S., and Greber, U.F. (2011). Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells. Nat Commun 2, 391.
99. Mamber, C., Verhaagen, J., and Hol, E.M. (2010). In vivo targeting of subventricular zone astrocytes. Prog Neurobiol 92, 19-32.
100. Mandel, R.J., Snyder, R.O., and Leff, S.E. (1999). Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 160, 205-214.
101. Manservigi, R., Argnani, R., and Marconi, P. (2010). HSV Recombinant Vectors for Gene Therapy. Open Virol J 4, 123-156.
102. Marks, W.J., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., Bakay, R., Watts, R., Guthrie, B., Jankovic, J., Simpson, R., Tagliati, M., Alterman, R., Stern, M., Baltuch, G., Starr, P.A., Larson, P.S., Ostrem, J.L., Nutt, J., Kieburtz, K., Kordower, J.H., and Olanow, C.W. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology 9, 1164-1172.
103. Martinet, O., Schreyer, N., Reis, E.D., and Joseph, J.M. (2003). Encapsulation of packaging cell line results in successful retroviral-mediated transfer of a suicide gene in vivo in an experimental model of glioblastoma. Eur J Surg Oncol 29, 351-357.
104. Miletic, H., Fischer, Y.H., Neumann, H., Hans, V., Stenzel, W., Giroglou, T., Hermann, M., Deckert, M., and Von Laer, D. (2004). Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther 15, 1091-1100.
105. Miller, F.D., and Gauthier, A.S. (2007). Timing is everything: making neurons versus glia in the developing cortex. Neuron 54, 357-369.
106. Molofsky, A.V., Krencik, R., Ullian, E.M., Tsai, H.H., Deneen, B., Richardson, W.D., Barres, B.A., and Rowitch, D.H. (2012). Astrocytes and disease: a neurodevelopmental perspective. Genes Dev 26, 891-907.
107. Moran, E. (1993). Interaction of adenoviral proteins with pRB and p53. FASEB J 7, 880-885.
108. Murphy, A.M., and Rabkin, S.D. (2013). Current status of gene therapy for brain tumors. Transl Res 161, 339-354.
109. Nakai, H., Yant, S.R., Storm, T.A., Fuess, S., Meuse, L., and Kay, M.A. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75, 6969-6976.
110. Naldini, L., Blomer, U., Gage, F.H., Trono, D., and Verma, I.M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93, 11382-11388.
111. O'carroll, D., and Schaefer, A. (2013). General principals of miRNA biogenesis and regulation in the brain. Neuropsychopharmacology 38, 39-54.
112. Opie, S.R., Warrington, K.H., Jr., Agbandje-Mckenna, M., Zolotukhin, S., and Muzyczka, N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77, 6995-7006.
113. Packer, R.J., Raffel, C., Villablanca, J.G., Tonn, J.C., Burdach, S.E., Burger, K., Lafond, D., Mccomb, J.G., Cogen, P.H., Vezina, G., and Kapcala, L.P. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92, 249-254.
114. Page, K.A., Landau, N.R., and Littman, D.R. (1990). Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 64, 5270-5276.
115. Palfi, S. (2008). Towards gene therapy for Parkinson's disease. Lancet Neurol 7, 375-376.
116. Parker, J.N., Bauer, D.F., Cody, J.J., and Markert, J.M. (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6, 558-569.
117. Pertusa, M., Garcia-Matas, S., Mammeri, H., Adell, A., Rodrigo, T., Mallet, J., Cristofol, R., Sarkis, C., and Sanfeliu, C. (2008). Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging 29, 1366-1379.
118. Pfrieger, F.W., and Slezak, M. (2012). Genetic approaches to study glial cells in the rodent brain. Glia 60, 681-701.
119. Portales-Casamar, E., Swanson, D.J., Liu, L., De Leeuw, C.N., Banks, K.G., Ho Sui, S.J., Fulton, D.L., Ali, J., Amirabbasi, M., Arenillas, D.J., Babyak, N., Black, S.F., Bonaguro, R.J., Brauer, E., Candido, T.R., Castellarin, M., Chen, J., Chen, Y., Cheng, J.C., Chopra, V., Docking, T.R., Dreolini, L., D'souza, C.A., Flynn, E.K., Glenn, R., Hatakka, K., Hearty, T.G., Imanian, B., Jiang, S., Khorasan-Zadeh, S., Komljenovic, I., Laprise, S., Liao, N.Y., Lim, J.S., Lithwick, S., Liu, F., Liu, J., Lu, M., Mcconechy, M., Mcleod, A.J., Milisavljevic, M., Mis, J., O'connor, K., Palma, B., Palmquist, D.L., Schmouth, J.F., Swanson, M.I., Tam, B., Ticoll, A., Turner, J.L., Varhol, R., Vermeulen, J., Watkins, R.F., Wilson, G., Wong, B.K., Wong, S.H., Wong, T.Y., Yang, G.S., Ypsilanti, A.R., Jones, S.J., Holt, R.A., Goldowitz, D., Wasserman, W.W., and Simpson, E.M. (2010). A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc Natl Acad Sci U S A 107, 16589-16594.
120. Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Srivastava, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5, 71-77.
121. Rabinowitz, J.E., and Samulski, J. (1998). Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 9, 470-475.
122. Rainov, N.G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11, 2389-2401.
123. Ram, Z., Culver, K.W., Oshiro, E.M., Viola, J.J., Devroom, H.L., Otto, E., Long, Z., Chiang, Y., Mcgarrity, G.J., Muul, L.M., Katz, D., Blaese, R.M., and Oldfield, E.H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vectorproducing cells. Nat Med 3, 1354-1361.
124. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M., and Oldfield, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53, 83-88.
125. Ram, Z., Walbridge, S., Shawker, T., Culver, K.W., Blaese, R.M., and Oldfield, E.H. (1994). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81, 256-260.
126. Regan, M.R., Huang, Y.H., Kim, Y.S., Dykes-Hoberg, M.I., Jin, L., Watkins, A.M., Bergles, D.E., and Rothstein, J.D. (2007). Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci 27, 6607-6619.
127. Rubin, B.A., and Rorke, L.B. (1994). Adenovirus vaccines, in Vaccines, eds. S.A. Plotkin & E.A. Mortimer. (Philadelphia: W. B. Saunders), pp. 475-502.
128. Rubio, N., and Martin-Clemente, B. (2002). Binding of adenovirus to its receptors in mouse astrocytes induces c-fos proto-oncogene and apoptosis. Virology 297, 211-219.
129. Russell, S.J., Peng, K.W., and Bell, J.C. (2012). Oncolytic virotherapy. Nat Biotechnol 30, 658-670.
130. Saugstad, J.A. (2010). MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab 30, 1564-1576.
131. Savchenko, V.L., Mckanna, J.A., Nikonenko, I.R., and Skibo, G.G. (2000). Microglia and astrocytes in the adult rat brain: Comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity. Neuroscience 96, 195- 203.
132. Schnepp, B.C., Jensen, R.L., Chen, C.L., Johnson, P.R., and Clark, K.R. (2005). Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 79, 14793-14803.
133. Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A.G., and Barbier, N. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10, 2325-2335.
134. Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H., and Asokan, A. (2011). Terminal NLinked Galactose Is the Primary Receptor for Adeno-associated Virus 9. Journal of Biological Chemistry 286, 13532-13540.
135. Shevtsova, Z., Malik, J.M., Michel, U., Bahr, M., and Kugler, S. (2005). Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90, 53-59.
136. Smirnova, L., Grafe, A., Seiler, A., Schumacher, S., Nitsch, R., and Wulczyn, F.G. (2005). Regulation of miRNA expression during neural cell specification. Eur J Neurosci 21, 1469-1477.
137. Smith, G.M., Hale, J., Pasnikowski, E.M., Lindsay, R.M., Wong, V., and Rudge, J.S. (1996). Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro. Exp Neurol 139, 156-166.
138. Sofroniew, M.V., and Vinters, H.V. (2010). Astrocytes: biology and pathology. Acta Neuropathol 119, 7-35.
139. Soudais, C., Laplace-Builhe, C., Kissa, K., and Kremer, E.J. (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 15, 2283-2285.
140. Stein, C.S., Martins, I., and Davidson, B.L. (2005). The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol Ther 11, 382-389.
141. Tuszynski, M.H., Thal, L., Pay, M., Salmon, D.P.UHS., Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G., Tong, G., Potkin, S.G., Fallon, J., Hansen, L., Mufson, E.J., Kordower, J.H., Gall, C., and Conner, J. (2005). A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11, 551-555.
142. Vite, C.H., Passini, M.A., Haskins, M.E., and Wolfe, J.H. (2003). Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 10, 1874-1881.
143. Walker, B.A., Hengst, U., Kim, H.J., Jeon, N.L., Schmidt, E.F., Heintz, N., Milner, T.A., and Jaffrey, S.R. (2012). Reprogramming axonal behavior by axon-specific viral transduction. Gene Ther 19, 947-955.
144. Wang, C., Wang, C.M., Clark, K.R., and Sferra, T.J. (2003). Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 10, 1528-1534.
145. Wang, C.Y., and Wang, S. (2006). Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter. Gene Ther 13, 1447-1456.
146. Wang, L., Lin, F., Wang, J., Wu, J., Han, R., Zhu, L., Difiglia, M., and Qin, Z. (2012). Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF. Brain Res 1449, 69-82.
147. Wanisch, K., and Yanez-Munoz, R.J. (2009). Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 17, 1316-1332.
148. Watson, D.J., Kobinger, G.P., Passini, M.A., Wilson, J.M., and Wolfe, J.H. (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 5, 528-537.
149. White, E., Bienemann, A., Taylor, H., Castrique, E., Bunnun, C., Wyatt, M., and Gill, S. (2011). An evaluation of site-specific immune responses directed against firstgeneration adenoviral vectors administered by convection-enhanced delivery. J Gene Med 13, 269-282.
150. Whitfield, T.W., Wang, J., Collins, P.J., Partridge, E.C., Aldred, S.F., Trinklein, N.D., Myers, R.M., and Weng, Z. (2012). Functional analysis of transcription factor binding sites in human promoters. Genome Biol 13, R50.
151. Wongsrikeao, P., Saenz, D., Rinkoski, T., Otoi, T., and Poeschla, E. (2011). Antiviral restriction factor transgenesis in the domestic cat. Nat Methods 8, 853-859.
152. Wu, Z., Asokan, A., Grieger, J.C., Govindasamy, L., Agbandje-Mckenna, M., and Samulski, R.J. (2006a). Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol 80, 11393-11397.
153. Wu, Z., Miller, E., Agbandje-Mckenna, M., and Samulski, R.J. (2006b). Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adenoassociated virus types 1 and 6. J Virol 80, 9093-9103.
154. Yang, S.H., Cheng, P.H., Banta, H., Piotrowska-Nitsche, K., Yang, J.J., Cheng, E.C., Snyder, B., Larkin, K., Liu, J., Orkin, J., Fang, Z.H., Smith, Y., Bachevalier, J., Zola, S.M., Li, S.H., Li, X.J., and Chan, A.W. (2008). Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453, 921-924.
155. Yla-Herttuala, S. (2012). Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20, 1831-1832.
156. Zemp, F.J., Corredor, J.C., Lun, X., Muruve, D.A., and Forsyth, P.A. (2010). Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 21, 103-117.
157. Zhang, Y., and Barres, B.A. (2010). Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr Opin Neurobiol 20, 588-594.